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ABSTRACT
Background: This first-in-human study evaluated AMG 208, a small-molecule MET 
inhibitor, in patients with advanced solid tumors.
Methods: Three to nine patients were enrolled into one of seven AMG 208 dose 
cohorts (25, 50, 100, 150, 200, 300, and 400 mg). Patients received AMG 208 orally on 
days 1 and days 4–28 once daily. The primary objectives were to evaluate the safety, 
tolerability, pharmacokinetics, and maximum tolerated dose (MTD) of AMG 208.
Results: Fifty-four patients were enrolled. Six dose-limiting toxicities were 
observed: grade 3 increased aspartate aminotransferase (200 mg), grade 3 
thrombocytopenia (200 mg), grade 4 acute myocardial infarction (300 mg), grade 3 
prolonged QT (300 mg), and two cases of grade 3 hypertension (400 mg). The MTD 
was not reached. The most frequent grade ≥ 3 treatment-related adverse event was 
anemia (n = 3) followed by hypertension, prolonged QT, and thrombocytopenia (two 
patients each). AMG 208 exposure increased linearly with dose; mean plasma half-
life estimates were 21.4–68.7 hours. One complete response (prostate cancer) and 
three partial responses (two in prostate cancer, one in kidney cancer) were observed. 
Conclusions: In this study, AMG 208 had manageable toxicities and showed 
evidence of antitumor activity, particularly in prostate cancer.
INTRODUCTION
The receptor tyrosine kinase MET mediates multiple 
cellular processes, including proliferation, survival, 
migration, and invasion in normal and tumor cells [1-
3]. MET can be activated through various mechanisms, 
such as ligand-dependent activation through binding of 
hepatocyte growth factor (HGF), and ligand-independent 
activation through overexpression, gene amplification, and 
activating mutations [1]. MET is often dysregulated in 
various cancers, including lymphoma, melanoma, gastric, 
lung, colorectal, head and neck, renal, and ovarian [4-
11], providing a strong rationale for targeting MET [1-3]. 
Elevated MET expression has been correlated with poor 
prognosis [7], and MET amplification has been associated 
with drug resistance to epidermal growth factor receptor 
(EGFR) inhibitors [12, 13]. Preclinical data suggest that 
concurrently inhibiting the MET and vascular endothelial 
growth factor (VEGF) pathways has synergistic effects 
[14].
AMG 208 is a small-molecule MET inhibitor 
with a 50% inhibitory concentration (IC50) against wild-
type MET of 5.2 nM. At higher concentrations, AMG 
208 inhibited other kinases, such as VEGF receptor 
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2 (VEGF-R2, IC50 = 112 nM; data on file). AMG 208 
suppressed proliferation and induced apoptosis in human 
tumor xenograft models (data on file).
We conducted a first-in-human study of AMG 208 
to investigate its safety, tolerability, pharmacokinetics, 
and pharmacodynamics in patients with advanced solid 
tumors (ClinicalTrials.gov identifier: NCT00813384). We 
also evaluated antitumor activity and MET expression, 
amplification, and mutation status as potential biomarkers 
of response.
RESULTS
Patient characteristics and disposition
Fifty-four patients were enrolled and received ≥1 
dose of AMG 208: 25 mg (n = 6), 50 mg (n = 4), 100 
mg (n = 4), 150 mg (n = 3), 200 mg (n = 16), 300 mg 
(n = 10), and 400 (n = 11). The first patient enrolled on 
December 29, 2008, and the last patient completed the 
study on July 25, 2012. In the 25-mg cohort, the first three 
patients enrolled were not evaluable (did not complete the 
dose-limiting toxicity [DLT] assessment period defined as 
the first 28 days of treatment), so three additional patients 
were enrolled. Table 1 summarizes demographics and 
baseline characteristics. The most common primary tumor 
types were prostate (18.5%) followed by colon (11.1%), 
esophageal (11.1%), and non-small cell lung cancer 
(NSCLC, 11.1%). Reasons for discontinuing AMG 208 
treatment included disease progression (64.8%), adverse 
events (AEs, 16.7%), withdrawal of partial consent 
(5.6%), and requirement for alternative therapy (3.7%). 
The median number of AMG 208 doses received per 
patient was 27 (range, 1–671) and was highest in the 400-
mg cohort (110; range, 9–306). Three (5.6%) patients had 
dose reductions.
Safety and tolerability
Six patients had DLTs: 200 mg (n = 2), 300 mg (n 
= 2), and 400 mg (n = 2). In the 200-mg cohort, seven 
patients were initially enrolled, of whom two had a DLT 
(grade 3 increased aspartate aminotransferase [AST] 
and grade 3 thrombocytopenia), four completed without 
a DLT, and one withdrew early from the study due to 
disease progression. The protocol was amended to de-
escalate to 150 mg and then re-escalate to 200 mg (Figure 
1); three additional patients were then enrolled to the 200-
mg cohort, of whom two completed without a DLT, and 
Figure 1: Schematic overview of the dose escalation cohorts. Three to nine patients were enrolled into one of the following seven 
AMG 208 dose cohorts: 25, 50, 100, 150, 200, 300, and 400 mg. A standard 3+3 design was followed in cohorts 1–3, and a modified 3+3+3 
design was followed in cohorts 4–7. The protocol was amended to evaluate an intermediate dose level of 150 mg after two DLTs (out of six 
patients) were observed with 200 mg AMG 208 (red arrow); re-escalation to 200 mg occurred after the 150-mg dose cohort was considered 
well tolerated (red arrow). 
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one withdrew from the study due to stroke, which was 
not considered related to AMG 208. The 200-mg cohort 
was expanded to four additional patients, of whom three 
completed without a DLT, and one withdrew early from 
the study. Per protocol, two additional patients were 
allowed to enroll to the 200-mg cohort because of MET-
positive status. In the 300-mg cohort, seven patients were 
initially enrolled, of whom two had a DLT (grade 4 acute 
myocardial infarction and grade 3 prolonged QT), four 
completed without DLT, and one withdrew early from the 
study. Three additional patients were enrolled to the 300-
mg cohort, and these three completed without a DLT. In 
Table 1: Demographics and baseline characteristics
All Patients
(N = 54)
Sex, n (%)
Male 36 (66.7)
Female 18 (33.3)
Race, n (%)
White/Caucasian 39 (72.2)
Hispanic/Latino 7 (13.0)
Black/African American 5 (9.3)
Asian 3 (5.6)
Age, median (range), y 60.5 (39 –80)
ECOG performance status at baseline, n (%)
0 28 (52)
1 26 (48)
Disease stage, n (%)
II 1 (2)
III 4 (7)
IV 48 (89)
Unknown 1 (2)
Primary tumor type, n (%)
Prostate 10 (18.5)
Colon 6 (11.1)
Esophageal 6 (11.1)
Non-small cell lung 6 (11.1)
Kidney 5 (9.3)
Head and neck squamous cell carcinoma 3 (5.6)
Bladder 2 (3.7)
Carcinoma of unknown origin 2 (3.7)
Malignant melanoma 2 (3.7)
Ovarian 2 (3.7)
Stomach 1 (1.9)
Cervix 1 (1.9)
Oral 1 (1.9)
Pancreas 1 (1.9)
Soft tissue sarcoma 1 (1.9)
Uterine 1 (1.9)
Othera 4 (7.4)
Prior radiotherapy, n (%) 32 (59.3)
Number of prior chemotherapy regimens, n (%)
1 4 (7)
2 15 (28)
≥3 35 (65)
aIncludes adenoid cystic carcinoma, appendiceal adenocarcinoma, metastatic insular 
thyroid cancer, and poorly differentiated adenocarcinoma of the gallbladder. ECOG, 
Eastern Cooperative Oncology Group.
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the 400-mg cohort, eight patients were initially enrolled, 
of whom two had a DLT (both grade 3 hypertension), four 
completed without a DLT, and two withdrew early from 
the study. Three additional patients were enrolled to the 
400-mg cohort, and these three completed without a DLT. 
A maximum tolerated dose (MTD) was not determined. 
Forty-five patients had treatment-related AEs, the 
most common being fatigue (44.4%) and nausea (33.3%) 
(Table 2). Thirteen patients reported grade ≥3 treatment-
related AEs, with anemia (5.6%), hypertension (3.7%), 
prolonged QT (3.7%), and thrombocytopenia (3.7%) being 
the most frequently reported (Table 2). 
Seven patients reported treatment-related AEs 
considered serious: 200 mg (n = 3; increased AST, 
thrombocytopenia, and increased serum creatinine), 300 
mg (n = 1; acute myocardial infarction), and 400 mg (n = 
3; hypertension, pulmonary embolism, and neutropenia). 
Of these seven patients, three had treatment-related serious 
AEs leading to AMG 208 discontinuation: 200 mg (n 
= 1; increased AST), 300 mg (n = 1; acute myocardial 
infarction), and 400 mg (n = 1; hypertension). The 
increased AST was observed in a 43-year-old female with 
stage IV papillary renal cell carcinoma who developed 
grade 3 elevation of AST with grade 1 elevation of 
alanine aminotransferase (ALT) on day 8 of the study. 
AMG 208 was discontinued, and the AST and ALT were 
normalized within 1 week. The investigator did not report 
any relevant concomitant medications, and there were 
Table 2: Treatment-related adverse events
AMG 208 Dose Cohort (mg)
All 
Patients 
(N = 54)
25 mg 
(n = 6)
50 mg 
(n = 4)
100 mg 
(n = 4)
150 mg 
(n = 3)
200 mg 
(n = 16)
300 mg 
(n = 10)
400 mg 
(n = 11)
Patients with any grade 
AEs, n (%) 45 (83.3) 2 (33.3) 3 (75.0) 4 (100.0) 3 (100.0) 14 (87.5) 8 (80.0) 11 (100.0)
Fatigue 24 (44.4) 2 (33.3) 2 (50.0) 2 (50.0) 3 (100.0) 3 (18.8) 4 (40.0) 8 (72.7)
Nausea 18 (33.3) 1 (16.7) 2 (50.0) 0 (0) 1 (33.3) 2 (12.5) 4 (40.0) 8 (72.7)
Hypertension 12 (22.2) 0 0 1 (25.0) 0 6 (37.5) 2 (20.0) 3 (27.3)
Diarrhea 11 (20.4) 0 0 0 0 3 (18.8) 2 (20.0) 6 (54.5)
Anemia 10 (18.5) 0 0 2 (50.0) 2 (66.7) 4 (25.0) 1 (10.0) 1 (9.1)
Increased AST 9 (16.7) 0 0 0 2 (66.7) 4 (25.0) 0 3 (27.3)
Decreased appetite 9 (16.7) 0 1 (25.0) 0 0 2 (12.5) 3 (30.0) 3 (27.3)
Leukopenia 9 (16.7) 0 0 0 3 (100.0) 3 (18.8) 1 (10.0) 2 (18.2)
Increased ALT 8 (14.8) 0 0 0 1 (33.3) 4 (25.0) 0 3 (27.3)
Achromotrichia acquired 7 (13.0) 0 0 0 0 2 (12.5) 2 (20.0) 3 (27.3)
Thrombocytopenia 7 (13.0) 0 0 0 1 (33.3) 2 (12.5) 1 (10.0) 3 (27.3)
Vomiting 6 (11.1) 0 1 (25.0) 0 0 0 1 (10.0) 4 (36.4)
Increased blood creatinine 5 (9.3) 0 0 0 1 (33.3) 3 (18.8) 1 (10.0) 0
Hypomagnesemia 5 (9.3) 0 0 1 (25.0) 0 3 (18.8) 0 1 (9.1)
Patients with grade ≥3 
AEs, n (%) 13 (24.1) 0 0 1 (25.0) 0 3 (18.8) 3 (30.0) 6 (54.5)
Anemia 3 (5.6) 0 0 1 (25.0) 0 1 (6.3) 1 (10.0) 0
Hypertension 2 (3.7) 0 0 0 0 0 0 2 (18.2)
Prolonged 
electrocardiogram QT 2 (3.7) 0 0 0 0 0 1 (10.0) 1 (9.1)
Thrombocytopenia 2 (3.7) 0 0 0 0 1 (6.3) 0 1 (9.1)
Acute myocardial 
infarction 1 (1.9) 0 0 0 0 0 1 (10.0) 0
Increased AST 1 (1.9) 0 0 0 0 1 (6.3) 0 0
Increased blood creatinine 1 (1.9) 0 0 0 0 1 (6.3) 0 0
Increased blood creatinine 
phosphokinase 1 (1.9) 0 0 0 0 0 0 1 (9.1)
Hyperglycemia 1 (1.9) 0 0 0 0 0 0 1 (9.1)
Neutropenia 1 (1.9) 0 0 0 0 0 0 1 (9.1)
Decreased neutrophil count 1 (1.9) 0 0 0 0 0 0 1 (9.1)
Pulmonary embolism 1 (1.9) 0 0 0 0 0 0 1 (9.1)
Any grade treatment-related AEs occurring in ≥5 patients overall and any grade ≥3 treatment-related AEs are shown. AEs 
were coded using MedDRA version 15.0. AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase. 
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no reports of other liver function test abnormalities. The 
acute myocardial infarction was observed in a 67-year-
old male with stage IV NSCLC who had a history of 
hypertension, hyperlipidemia, cerebrovascular accident, 
and coronary artery disease. The patient reported chest 
pain with associated shortness of breath 10 and 14 days 
after receiving the first dose of AMG 208, and he was 
diagnosed with ST elevation myocardial infarction. 
Table 3: Tumor response by MET analysis
Cytoplasmic IHC Membrane IHC
Dose 
(mg)
Primary Tumor 
Type
Best 
Tumor 
Response
Best % 
Change 
in SLDa
% Change 
in Sum of 
SUVmaxb
Sequencing FISH % Pos H-score
MAX 
SI
% 
Pos H-score
MAX 
SI
25 Colon PD 30.65 - M Neg 90 90 1+ 0 0 0
Esophageal SD 3.39 -32.00 ND ND 100 200 3+ 1 1 1+
NSCLC SD 5.00 -4.94 M Neg 10 10 1+ 50 50 1+
50 Esophageal PD 20.97 -21.55 W Neg 80 80 1+ 60 70 2+
Carcinoma of 
unknown origin SD -6.45 - W Neg 0 0 0 0 0 0
100 Appendiceal adenocarcinoma SD 1.39 - W Neg 95 155 2+ 10 10 1+
Bladder SD 2.63 -3.70 F Neg 0 0 0 0 0 0
Carcinoma of 
unknown origin SD -5.02 -31.68 W Neg 1 1 1+ 0 0 0
NSCLC SD 14.05 - F ND 15 15 1+ 0 0 0
150 Esophageal PD 2.02 -16.67 W ND ND ND ND ND ND ND
Melanoma PD 31.43 -6.57 W Neg 0 0 0 0 0 0
200 Kidney PR -32.51 -39.68 ND ND 95 105 2+ 40 70 3+
Ovarian SD 10.56 -13.98 ND Neg 60 60 1+ 0 0 0
Esophageal SD 5.13 -6.67 ND Neg 95 145 2+ 60 70 2+
Colon SD 6.45 -6.06 ND Neg 99 109 2+ 20 20 1+
Prostate PD 33.33 - F ND ND ND ND ND ND ND
Colon PD 8.92 - W Neg 80 85 2+ 10 10 1+
Esophageal PD 34.37 4.38 F ND 25 30 2+ 1 1 1+
Kidney SD -22.22 -33.75 ND Neg 95 137 3+ 63 67 3+
Bladder PD 32.35 34.26 F Neg 10 11 2+ 10 16 3+
300 Prostate CR - - W Neg ND ND ND ND ND ND
Kidney PD 10.32 1.49 M Neg ND ND ND ND ND ND
NSCLC SD - -22.22 W ND ND ND ND ND ND ND
Stomach SD 5.94 -20.19 W Neg ND ND ND ND ND ND
Prostate SD - -36.40 W Neg ND ND ND ND ND ND
Prostate SD - - W Neg ND ND ND ND ND ND
Ovarian SD 19.35 - W Neg ND ND ND ND ND ND
400 Prostate PR -32.50 -40.54 F ND ND ND ND ND ND ND
Head and neck 
squamous cell 
carcinoma
SD -20.00 - F ND ND ND ND ND ND ND
Prostate SD 5.19 -41.83 ND Neg ND ND ND ND ND ND
Prostate SD -14.29 - W Pos ND ND ND ND ND ND
Prostate PR -41.18 - ND Neg ND ND ND ND ND ND
Poorly 
differentiated 
adenocarcinoma 
of gallbladder
SD 5.17 - W Neg ND ND ND ND ND ND
Patients with available data for MET biomarker testing and evaluable best tumor response (site reads), percent change in 
SLD (site reads), or percent change in sum of SUVmax are shown. aFrom baseline. b1 cm spot; week 5 day 29. F, failed; M, 
mutated; MAX SI, maximum staining intensity; SD, stable disease; SLD, sum of the longest diameter; ND, not determined; 
Neg, negative; PD, progressive disease; Pos, positive; PR, partial response; W, wild type.
Oncotarget18698www.impactjournals.com/oncotarget
Cardiac catheterization revealed ulcerated plaques in 
the right coronary artery and moderate/diffuse disease of 
the left anterior descending and circumflex arteries. The 
hypertension was observed in a 76-year-old male with 
stage IV prostate cancer who had a history of controlled 
hypertension. His blood pressure was elevated on days 
7 to 10 of the study and ranged from 178/88 to 210/90. 
There were no other predisposing risk factors for elevated 
blood pressure except for the presence of bone pain before 
and during the event. AMG 208 was discontinued, and the 
event resolved within 4 days of discontinuation. 
Five patients died during the study, and none 
were considered treatment related (disease progression, 
n = 4; pulmonary hemorrhage, n = 1). The patient with 
pulmonary hemorrhage was diagnosed with pulmonary 
hypertension and pulmonary aspergillosis and had clear 
evidence of metastatic disease in the lung; thus, the grade 
5 pulmonary hemorrhage was considered related to the 
disease. 
Pharmacokinetics
AMG 208 pharmacokinetics was estimated for 53 
patients who received ≥1 dose of AMG 208. After oral 
administration, linear increases of approximately 10- to 
12-fold were observed over the 25- to 400-mg dose range 
in maximum concentration (Cmax) and area under the 
concentration-time curve from time 0 to 24 hours (AUC0–
24h) exposures. In the 400-mg cohort, mean Cmax and AUC0–
24h exposures on day 28 were 18.4 µg/mL and 245 µg•h/
mL, respectively. Mean plasma concentration-time profiles 
from each cohort are shown for 36 patients who completed 
28 days of AMG 208 dosing (Figure 2). AMG 208 mean 
plasma half-life estimates ranged from 21.4 to 68.7 hours 
and were consistent with a 1.81- to 3.43-fold accumulation 
observed after 28 days of repeated dosing.
Pharmacodynamics
The pharmacodynamic effects of AMG 208 on the 
following circulating biomarkers were evaluated: soluble 
MET, HGF, placental growth factor (PlGF), VEGF-R2, 
c-Kit, sFlt-1, VEGF, serum C-terminal telopeptide of 
type 1 collagen (sCTx), type 1 procollagen N-terminal 
propeptide (P1NP), and bone alkaline phosphatase 
(BALP). PlGF demonstrated a pharmacodynamic response 
to AMG 208; mean PlGF levels increased the most with 
the 400-mg dose at all time points (Figure 3). No other 
circulating biomarkers demonstrated a pharmacodynamic 
effect.
Antitumor activity
Forty-three patients had responses evaluated at the 
sites based on computed tomography (CT) and/or bone 
scans using the modified Response Evaluation Criteria 
for Solid Tumors (RECIST) version 1.0. Eleven patients 
went off study early (due to disease progression [n = 3], 
DLT [n = 3], AE [n = 3], partial consent withdrawn [n = 
1], or ineligibility determined after first dose [n = 1]) and 
had no follow-up scans for response evaluation. Figure 
4A shows the change in the sum of the longest diameter 
for the best postdose response. There were one complete 
response (CR) and three partial responses (PRs). The CR 
was observed in a 66-year-old patient with prostate cancer 
at week 18, based on nontarget lesions evaluated by bone 
scans (300-mg cohort, Figure 5A); this patient was on the 
study for approximately 57 weeks. One confirmed PR 
was observed in a patient with kidney cancer at week 9 
(200-mg cohort); this patient had a 33% tumor reduction 
and was on the study for approximately 23 weeks. 
Two unconfirmed PRs were observed in two patients 
with prostate cancer (both 400-mg cohort). One patient 
had a 33% tumor reduction and was on the study for 
Figure 2: Plasma concentration time profiles of AMG 208 on days 1 and 28 following oral administration on days 1 
and 4 to 28 once daily. Data points represent means ± standard deviations.
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approximately 31 weeks. The second patient had a 41% 
tumor reduction and was on the study for approximately 
35 weeks. Twenty-eight patients had stable disease, and 11 
patients had progressive disease.
Forty-two patients had responses evaluated by 
independent central review based on CT and/or bone 
Figure 3: PlGF mean ratio to baseline by treatment arm. Patients who received ≥1 dose of AMG 208 and had a measurable 
baseline concentration of PlGF were analyzed. The mean log ratio to baseline and standard error were computed, and the results were anti-
logged and presented as mean ratio to baseline. Results from day 64 were excluded due to small sample size.
Figure 4: Antitumor activity of AMG 208. A. The percent change in the sum of the longest diameter (SLD) for the best postdose 
response is shown. Patients with baseline and ≥1 post-baseline SLD for the target lesion were analyzed. Thirty-seven patients are shown, 
and 17 were not included because of the following reasons: five patients were evaluated with nontarget lesions only (four prostate and one 
NSCLC), one patient with NSCLC had progressive disease due to a new lesion, and 11 patients did not have baseline and/or post-baseline 
scans. B. The percent change in the sum of 18F-FLT SUVmax (1 cm spot) at week 5 day 29. Only patients with both baseline and week 5 
day 29 SUVmax (1 cm spot) are shown. *Prostate cancer. 
†Carcinoma of unknown origin. NSCLC, non-small cell lung cancer; SUVmax, 
maximum standardized uptake value.
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scans. Eleven patients went off study early and had no 
follow-up scans, and one patient had incomplete coverage 
of target lesion at the follow-up scan and could not be 
evaluated. Thirty-three patients had stable disease, and 
nine patients had progressive disease.
Antitumor activity was further evaluated by 
3’-deoxy-3’-18F-fluorothymidine (18F-FLT) positron 
emission tomography (PET) scans (Figure 4B). Twenty-
seven patients had evaluable baseline and week 5 18F-FLT-
PET scans. Seven patients had ≥25% reduction from 
baseline in 18F-FLT uptake (maximum standardized uptake 
value [SUVmax]) at week 5 day 29, indicating a treatment 
response in tumor cell proliferation. Two of the seven 
proliferative responders (1 patient with prostate cancer 
[Figure 5B] and 1 patient with kidney cancer) also had PR 
by RECIST 1.0 (33% reduction based on site read).
Figure 5: A. Complete response in a 66-year-old patient with prostate cancer treated with 300 mg AMG 208 (bone scans). At baseline, 
bone metastasis was present at T4 and L1. At week 18, evidence of bone metastasis was not observed. B. Partial response in a 63-year-old 
patient with prostate cancer treated with 400 mg AMG 208 (18F-FLT-PET and CT scans).
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Of the 10 patients with prostate cancer, three 
patients had a response per modified RECIST 1.0. As 
mentioned earlier, one patient with prostate cancer had 
a CR on bone scan (300-mg cohort). Two patients with 
prostate cancer had unconfirmed PRs based on CT scans, 
both in the 400-mg cohort. One patient had a 33% tumor 
reduction at week 17. The second patient had a 41% tumor 
reduction at week 27. Furthermore, three patients with 
prostate cancer were proliferative responders (36%, 41%, 
and 42% reductions in 18F-FLT uptake).
Biomarkers
Twenty-two, 29, and 25 patients were analyzed for 
MET by immunohistochemistry (IHC), fluorescence in 
situ hybridization (FISH), and sequencing, respectively. 
No associations between response and MET testing were 
observed (Table 3).
DISCUSSION
In this first-in-human study of AMG 208, an oral 
MET inhibitor, the MTD was not reached at the highest 
dose tested (400 mg), and AMG 208 had manageable 
toxicities. The most common any grade AEs included 
fatigue and nausea; the most common grade ≥3 AE was 
anemia. DLTs were reported in six patients at the 200- to 
400-mg dose levels. 
Similar toxicities were observed with AMG 208 as 
seen with other multikinase VEGF/MET inhibitors. In 
clinical studies of cabozantinib, a multikinase MET and 
VEGF inhibitor, common AEs included fatigue, decreased 
appetite, and diarrhea [15, 16], AEs also observed with 
AMG 208. Moreover, in a phase 2 study, foretinib, a dual 
MET/VEGF-R2 inhibitor, had a similar toxicity profile to 
AMG 208; common AEs included fatigue, hypertension, 
and gastrointestinal toxicities [17].
AMG 208 was orally bioavailable at the doses tested 
and exhibited a favorable pharmacokinetic profile. AMG 
208 exposures increased linearly up to the 400-mg dose 
level, and mean estimates of elimination half-life ranged 
from 21.4 to 68.7 hours. After 28 days of once daily 
AMG 208 dosing, mean unbound trough concentrations 
ranged from 12.3 to 199 nM, thus exceeding the in vitro 
IC50 estimate against wild-type MET (5.2 nM) at all dose 
levels. Among patients who received the 300- and 400-
mg AMG 208 doses, unbound trough concentrations 
approximated or slightly exceeded the in vitro IC50 against 
VEGF-R2 (112 nM), which might explain higher increases 
in mean PIGF levels that were observed at the 400 mg 
dose level.
AMG 208 showed encouraging antitumor activity 
in prostate cancer, as suggested by the CR, 2 PRs, and 3 
proliferative responses. In a phase 2 study of cabozantinib 
in prostate cancer, PFS was longer (23.9 versus 5.9 
weeks with cabozantinib versus placebo), and 72% of 
evaluable patients had regression in soft tissue lesions 
with cabozantinib treatment [15]. It was postulated that 
cabozantinib’s efficacy may be due to the simultaneous 
inhibition of MET and VEGF, and that the sole targeting 
of either the MET or VEGF pathways may not be 
sufficient in this disease. However, recent findings from 
the phase 3 study in castration-resistant prostate cancer 
showed no statistically significant improvement in OS 
with cabozantinib versus prednisone (median OS: 11 
versus 9.8 months) [18], indicating that the hypothesis that 
efficacy in prostate cancer is due to dual inhibition of MET 
and VEGF may not be justified. AMG 208 has a different 
target coverage profile than cabozantinib; hence, lack of 
efficacy with cabozantinib in the prostate cancer setting 
may not be of relevance to AMG 208. . Furthermore, in 
another study, androgen deprivation was associated with a 
switch to MET signaling in prostate cancer cells [19]. All 
10 patients with prostate cancer in the current study had 
previous androgen deprivation therapy.
Differences were observed between investigator-
assessed and centrally assessed tumor responses; these 
may be attributable to inadequacies of RECIST 1.0, 
which considers bone and cystic lesions as nonmeasurable 
lesions. Some lesions defined as responders in the site 
reads per RECIST 1.0 were possibly bone or cystic lesions 
that the investigators considered as measurable lesions. 
Moreover, different lesions may have been measured in 
the site and central reads.
Patients selected by MET protein overexpression 
and MET amplification in gastroesophageal cancers [20, 
21], MET germline mutations in papillary renal cell cancer 
[17], and chromosome polyploidy in gastric cancer [22] 
have been associated with response to MET inhibitors. 
However, in our exploratory and retrospective analysis 
of MET in the study, no apparent associations between 
MET expression, amplification, and mutation status were 
observed. The results suggest that increased levels of MET 
expression by IHC did not correlate with response to MET 
inhibition as observed with AMG 208. One consideration 
is that some patients were treated during dose-escalation 
of AMG 208 and may not have received adequate doses to 
inhibit the pathway. Moreover, there may be a minimum 
threshold at which the MET/CEP7 ratio confers MET 
dependency and sensitivity to AMG 208, similar to recent 
reports of HER-2 and trastuzumab in gastric cancer [23]. 
Finally, these analyses were limited by the small sample 
size.
AMG 208 at 400 mg was the highest administered 
dose in this study. Although the MTD was not reached, 
the 400 mg dose was considered the recommended phase 
2 dose. AMG 208 was initially investigated as a MET 
inhibitor. As mentioned earlier, the responses observed 
in prostate cancer are likely a result of its multikinase 
activity, similar to cabozantinib. The study was stopped 
before enrollment into the dose expansion phase.
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It is hypothesized that inhibiting the MET pathway 
may overcome resistance to various therapies, including 
anti-EGFR inhibitors, platinum chemotherapy, and 
radiotherapy [24]. In a phase 1 study, tivantinib, a MET 
inhibitor and microtubule polymerization inhibitor 
[25], combined with erlotinib, an EGFR inhibitor, 
showed promising clinical activity with PR or stable 
disease observed in 15 of 32 patients [26]; in this same 
combination study, 6 of 8 patients with NSCLC achieved 
stable disease [26]. AMG 208 combined with other 
therapies has yet to be evaluated in clinical studies. 
Crosstalk between MET and other receptors, such as 
EGFR, HER2, integrin, and RON, may play a role in 
the development of resistance to targeted therapies, thus 
providing rationale to investigate MET pathway inhibitors 
in combination therapies.
MET continues to be an important target for cancer 
therapy. In addition to AMG 208, other small molecule 
MET inhibitors are under clinical development, some 
being selective inhibitors (eg, volitinib) and others being 
multikinase inhibitors (eg, crizotinib and cabozantinib) 
[24]. Several selective small molecule MET inhibitors 
have recently shown activity in early clinical trials, which 
include ABT-700 [27], AMG 337 [28], INC280 [29], 
MSC2156119J [30], SAR125844 [31], and volitinib [32]. 
Monoclonal antibodies targeting the MET pathway (eg, 
onartuzumab and rilotumumab) have also been evaluated 
in clinical trials [24]. Furthermore nanobodies to MET 
and indozoles have been tested in the preclinical setting as 
potential inhibitors of MET [33, 34].
In conclusion, AMG 208 was well tolerated as 
monotherapy at doses up to 400 mg in patients with 
advanced solid tumors. Future studies evaluating MET 
pathway inhibitors, particularly in prostate cancer and/or 
in combination therapies, are warranted.
MATERIALS AND METHODS
Eligibility criteria
Eligible patients (≥18 years) had a pathologically 
documented advanced solid tumor refractory to 
standard treatment or for which no standard therapy was 
available. Patients had measurable disease by RECIST 
version 1.0 [35]. Some patients with prostate cancer and 
nonmeasurable but evaluable disease (nontarget lesions 
only) were eligible (modified RECIST 1.0). Patients 
had an Eastern Cooperative Oncology Group (ECOG) 
performance status ≤2, life expectancy > 3 months, 
absolute neutrophil count ≥1.5 x 109/L, platelets ≥100 x 
109/L, hemoglobin > 9 g/dL, serum creatinine < 2 mg/
dL, calculated creatinine clearance > 60 mL/min, ALT 
or AST < 3 x the upper limit of normal (ULN; if liver 
involvement was present, < 5 x ULN), total bilirubin 1.5 
x ULN (if liver involvement was present, < 2 x ULN), 
alkaline phosphatase < 2 x ULN (if liver involvement or 
bone metastasis was present, ≤5 x ULN), and prothrombin 
or partial thromboplastin time < 1.5 x institutional ULN. 
Patients with primary central nervous system tumors or 
metastases were excluded. Each patient provided informed 
consent. Institutional review board approval was obtained 
for all study procedures.
Study design
This first-in-human, open-label study was to be 
conducted in two parts: (1) dose escalation and (2) dose 
expansion. In the dose escalation phase, 3–9 patients 
were enrolled into 1 of 7 dose cohorts (25, 50, 100, 150, 
200, 300, and 400 mg) of AMG 208 (Figure 1). Patients 
were administered AMG 208 as a single oral dose 
followed by a 72-hour treatment-free period to evaluate 
pharmacokinetics. Beginning on day 4, patients received 
daily oral doses of AMG 208 up to day 28. If no DLT 
was seen on days 1–28, patients with no evident disease 
progression received AMG 208.
A DLT was defined as any grade ≥3 nonhematologic 
or grade 4 hematologic AE occurring during the first 
28 days of treatment and possibly AMG 208 related. 
Treatment-related grade 3 thrombocytopenia could 
be considered a DLT if accompanied by grade ≥2 
hemorrhage. Fatigue (unless grade 3 and lasting > 7 days 
or grade 4) and lymphopenia were not considered DLTs. 
For patients with liver involvement or bone metastases, 
DLTs did not include elevations in alkaline phosphatase 
unless > 8 x ULN when the baseline level was 2–5 x 
ULN. For patients with liver involvement, DLTs did not 
include elevations in AST or ALT unless > 8 x ULN and 
the baseline level was 3–5 x ULN. Serum creatinine > 2.5 
mg/dL was considered a DLT.
In cohorts 1–3, a standard 3+3 design was followed. 
Enrollment into the next dose level occurred if no patients 
in the initial cohort experienced a DLT in the first 28 
days of treatment. If a DLT occurred, the cohort was 
expanded to six patients. Enrollment into the next dose 
level occurred if no DLTs were observed. If ≥2 DLTs 
were observed among the six patients, enrollment was 
to be stopped. Following a report of two DLTs (out of 
six patients) at the 200-mg dose level, the protocol was 
amended to evaluate an intermediate dose level of 150 
mg, and if well tolerated, re-escalation to the 200-mg 
dose level would occur. In cohorts 4–7, a modified 3+3+3 
design was followed in order toprovide additional data to 
ascertain dose selection; if a second DLT was observed, 
three additional patients were to be enrolled at the same 
dose level for a total of at least nine patients. If no DLTs 
were observed, dose escalation to the next dose level 
would occur.
To enrich this study, patients with tumors with MET 
amplification or mutation (MET positive) were allowed 
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to enroll into the study at any time at the current dose 
escalation cohort if a slot was available. If the current 
escalation cohort was full, eligible MET-positive patients 
were assigned to the highest dose level deemed safe and 
well tolerated at the time of enrollment.
Study objectives
The primary objectives were to evaluate the 
safety, tolerability, and pharmacokinetics of AMG 
208 and determine the MTD. Secondary objectives 
included evaluating tumor volume changes by CT 
or magnetic resonance imaging (MRI), decreases in 
tumor cell proliferation with 18F-FLT-PET scanning, 
potential biomarkers that reflect MET target coverage, 
and associations among response and MET expression, 
amplification, and mutation.
Safety
Safety was evaluated based on AEs, vital signs, 
clinical laboratory measurements, electrocardiograms, 
and physical examinations. AEs were graded according 
to the Common Terminology Criteria for Adverse Events, 
version 3.0.
Pharmacokinetics
AMG 208 pharmacokinetics was evaluated after 
a single dose and after 28 days of repeated daily dose 
administrations. AMG 208 plasma concentrations were 
determined by liquid chromatography-tandem mass 
spectrometry from samples collected predose, 0.5, 1, 2, 
4, 8, 24, and 48 or 72 hours after dosing on day 1, and 
pre-dose, 0.5, 1, 2, 4, 8, 24, and 48 hours on day 28. 
Pharmacokinetic parameters of observed Cmax, time of Cmax 
(tmax), and AUC0–24h were determined by noncompartmental 
analysis using Phoenix WinNonlin software version 6.3 
(Pharsight, St. Louis, MO). AMG 208 accumulation was 
estimated as a ratio of AUC0–24h on day 28 relative to day 
1 for patients who remained on the study for ≥28 days.
Pharmacodynamics
Serum samples were collected on days 1 and 2; 
predose on days 8, 15, 22, 28; on day 64; and every 4 
weeks thereafter and were analyzed for soluble MET, 
HGF, PlGF, VEGF-R2, c-Kit, sFlt-1, VEGF, sCTx, P1NP, 
and BALP. Pharmacodynamic effects were evaluated 
using time profiles with the mean ratio to baseline and 
standard error bars by treatment arms.
Levels of soluble MET, PlGF, VEGF, VEGF-R2, 
c-Kit, and sFlt-1 were quantified using multiplexed 
sandwich immunoassays with electrochemiluminescent 
detection (Meso Scale Discovery, Rockville, MD) 
following the manufacturer’s instructions. Levels of 
HGF were analyzed using an analyte-specific enzyme-
linked immunosorbent assay (ELISA; R&D Systems, 
Minneapolis, MN) following the manufacturer’s 
instructions and were compared to a standard curve. 
Samples were prepared and analyzed as previously 
described [36]. Levels of sCTx were quantified using 
the Serum Crosslaps ELISA (IDS Nordic, Herlev, 
Denmark) following the manufacturer’s instructions. 
Levels of P1NP were quantified by radioimmunoassay 
(RIA) using the UniQ PINP RIA kit following the 
manufacturer’s instructions and were compared to a 
standard curve (Covance Laboratories). Levels of BALP 
were quantified using the Access Ostase assay, a one-step 
immunoenzymatic assay, following the manufacturer’s 
instructions (Beckman Coulter, Indianapolis, IN).
Antitumor activity
Tumor response was assessed by contrast-enhanced 
CT or MRI at screening; week 5; week 9; and every 8 
weeks thereafter until disease progression and was 
evaluated by investigators based on modified RECIST 
version 1.0, which allowed some patients with metastatic 
prostate cancer and only nontarget bone lesions at 
screening to be evaluated with bone scans only. Response 
was also evaluated by an independent central imaging 
laboratory. Proliferative response was assessed by 18F-FLT-
PET scans at baseline and week 5. An antiproliferative 
response was defined as ≥25% reduction in 18F-FLT 
SUVmax.
Biomarkers
Archival formalin-fixed, paraffin-embedded 
(FFPE) tumor samples were analyzed for membrane 
and cytoplasmic MET expression by IHC at Mosaic 
Laboratories (Lake Forest, CA). Tumors were sectioned 
and stained with hematoxylin and eosin to identify regions 
of high tumor-cell content. IHC was performed using an 
anti-MET antibody (goat IgG, polyclonal, clone AF276) 
from R&D Systems. Staining was evaluated by a trained 
pathologist, and expression was evaluated for cellular 
localization of staining, intensity, subcellular localization, 
and percentage of tumor cells staining positive. Staining 
was evaluated on a semi-quantitative scale, and the 
percentage of tumor cells staining at the following 
intensities was recorded: 0 (unstained), 1+ (weak staining), 
2+ (moderate staining), and 3+ (strong staining). An 
H-score was calculated based on the percentage of cells 
stained at each intensity as follows: (3 x percent cells 
staining at 3+) + (2 x percent cells staining at 2+) + (1 x 
percent cells staining at 1+).
Archival FFPE tumor samples were analyzed for 
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MET amplification by FISH at Histogenex Laboratories 
(Antwerp, Belgium). Tumors were pretreated and stained 
with MET/SE7 Probe kit (KBI-10719, Kreatech, Durham, 
NC) using a VP2000 autostainer and a Thermobrite Hybrid 
system (Abbott Molecular, Des Plaines, IL) following the 
manufacturers’ instructions. Twenty nuclei were evaluated 
per sample, and the quantification of MET and SE7 signals 
was used to calculate the average MET copies per nuclei, 
average centromeric copies per nuclei, and the ratio of 
MET copies to SE7 copies.
DNA was extracted from archival FFPE tumor 
samples and interrogated for MET mutations using the 
SURVEYOR Nuclease assay (Transgenomic, Inc., Omaha, 
NE) followed by Sanger sequencing.
Statistical analysis
Descriptive statistics on continuous data included 
means, medians, standard deviations, and ranges. 
Categorical data were summarized by frequency counts 
and percentages. All patients who received ≥1 dose of 
AMG 208 were included in the safety analyses. Treatment-
emergent and treatment-related AEs occurring after the 
initial dose of AMG 208 and before the end of the study 
or 30 days after the last dose of AMG 208 (whichever 
occurred later) were presented descriptively. No formal 
analysis was done for efficacy. An exploratory summary 
of tumor response was produced. Descriptive analyses 
for biomarkers and associations between biomarkers and 
efficacy were produced. Results from the primary analysis 
(date of data cutoff: December 17, 2012) are presented.
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